[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351716-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351716-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","secondary-findings-after-multigene-panel-testing-in-7388-patients-with-suspected-cancer-predisposition-syndrome","Secondary findings after multigene panel testing in 7,388 patients with suspected cancer predisposition syndrome","","Secondary findings (SF) in hereditary cancer genes (HCG) were evaluated in a cohort of 7,388 individuals with suspected cancer predisposition syndrome over a six-year period (2019–2024). SF were defined as pathogenic/likely pathogenic variants not anticipated and not linked to the primary genetic testing indication. Clinical and laboratory geneticists reported SF in agreement, and patient preference for receiving SF was collected from medical documentation. Results showed 98.8% opted in; 42 SF (0.57%) were identified in 41 individuals, including ACMG-list and non-ACMG genes, plus mosaic findings.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/secondary-findings-after-multigene-panel-testing-in-7388-patients-with-suspected-cancer-predisposition-syndrome/351716/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/secondary-findings-after-multigene-panel-testing-in-7388-patients-with-suspected-cancer-predisposition-syndrome/351716.png","ImageObject",300,407,{"name":42,"@type":43},"Stanford","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How were secondary findings (SF) defined in this study?","Question",{"text":63,"@type":64},"SF were defined as pathogenic or likely pathogenic variants that were not anticipated and had no known correlation with the primary indication for genetic testing.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What proportion of patients opted in to receive secondary findings?",{"text":68,"@type":64},"The majority of patients (98.8%) opted in for disclosure of secondary findings.",{"name":70,"@type":61,"acceptedAnswer":71},"How many secondary findings were identified after multi-gene panel testing?",{"text":72,"@type":64},"The study identified 42 secondary findings in 41 individuals, corresponding to 0.57% of all tested individuals, including ACMG-list variants, non-ACMG genes, and mosaic findings.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351716,1790328338,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":115,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},2336477552062,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nSecondary findings after multigene panel testing in 7,388 patients with suspected cancer predisposition syndrome  \nEva Avsec1,2, Ana Blatnik1,2, Vita Šetrajčič Dragoš3, Petra Škerl3, Vida Stegel3 & Mateja Krajc1,2􀀍  \nOur study focused on the individuals’ preference for disclosure of secondary findings (SF) in hereditary cancer genes (HCG) and the frequency and type of SF after multi-gene panel testing (MGPT) in individuals with a suspected cancer predisposition syndrome (CPS) . SF are defined as pathogenic/likely pathogenic variants (P/LPV) that were not anticipated and without a known correlation to the primary indication for genetic testing. 7,388 individuals with a suspected CPS were tested in a 6-year period  \n2019–2024. SF in HCG were reported in agreement between clinical and laboratory geneticists. Data about the reported SF and preference to receive SF was acquired from patient medical documentation. Our study showed that majority of patients (98.8%) opted-in for disclosure of SF. We identified 42 SF (0.57% of all tested individuals) in 41 individuals. 11 were found in the HCG from theACMG list, 28 in HCG not included inACMG list and 3 were discovered in mosaic form. Our study provides important insight into frequency and type of SF in HCG in a cohort of individuals with suspected CPS. Further studies on larger cohorts are needed to better define the usefulness and potential risks of reporting SFin HCG in individuals without personal/family history of cancer.  \nKeywords Secondary findings, Genetic testing, Hereditary cancer  \nRising use of panel, exome, and genome analyses with next-generation sequencing has resulted in increased detection of secondary findings (SF) . American College of Medical Genetics and Genomics (ACMG) defines SF as pathogenic/likely pathogenic variants (P/LPV) in genes, which are a part of predefined list of potentially medically actionable genes and are deliberately searched for when a genetic test is performed, but are not related to the primary indication for genetic testing1. The first list was published in 2013 and has been updated several times since1–5. The latest ACMG 3.3 list with 84 genes was published in May 20256 and includes 28 hereditary cancer genes (HCG). According to the ACMG, this is a minimum list of genes intended to reduce morbidity and mortality, rather than a comprehensive list of all potentially actionable genetic results. They also acknowledged that some laboratories might include additional genes in their reports. The term SF should be distinguished from the term incidental finding, which refers to a result of a genetic test that is unexpected, unrelated to the primary indication for genetic testing and was discovered by chance and not during deliberate screening2.  \nLarge population studies7–12 show the frequency of all SF to be between 1 and 7%, while frequency of SFin HCG is estimated to be 0.4–3.1%13. There is lack of data on frequency of SF in HCG after multi-gene panel testing (MGPT) for suspected cancer predisposition syndrome (CPS), even though panel analysis is a common practice in cancer-related genetic testing14.  \nAccording to different authors7, 12, 15, majority of patients who undergo genetic testing opt-in for disclosure of medically actionable SF and this is also true for patients, tested for suspected CPS16, 17. Data on patient preference is still limited in the setting of MGPT for suspected CPS and was reported by Nambot et al., where 100% patients opted-in for disclosure of SF16. Analysis of a smaller Slovenian cohort similarly showed 98.4% of tested individuals consented to receiving SF in this setting18.  \nIn oncology, the extensive use of exome sequencing or multi-gene panel analyses to investigate CPS has uncovered P/LPV in HCG not directly related to the initial focus of genetic testing. Additionally, tumour tissue  \n1Department of Clinical Cancer Genetics, Institute o","cbCait8jeAJfHSM0","https://ap.wps.com/l/cbCait8jeAJfHSM0","pdf",1419390,"English","# Introduction\n## Definitions and background\n## Knowledge gaps in suspected cancer predisposition syndrome\n# Aim of the study\n# Materials and methods\n## Patients and genetic testing","[{\"question\":\"How were secondary findings (SF) defined in this study?\",\"answer\":\"SF were defined as pathogenic or likely pathogenic variants that were not anticipated and had no known correlation with the primary indication for genetic testing.\"},{\"question\":\"What proportion of patients opted in to receive secondary findings?\",\"answer\":\"The majority of patients (98.8%) opted in for disclosure of secondary findings.\"},{\"question\":\"How many secondary findings were identified after multi-gene panel testing?\",\"answer\":\"The study identified 42 secondary findings in 41 individuals, corresponding to 0.57% of all tested individuals, including ACMG-list variants, non-ACMG genes, and mosaic findings.\"}]","Secondary findings after multigene panel testing in 7,388 patients with suspected cancer predisposition syndrome | PDF",1790095489,23,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ec9a5e3a8e9ae42b0fc6773dec0ff739.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5012930e92d62579440b8b5a39a9c540.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f93c4ee83d6f64eeb995297876c04625.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/75511f4be50e7ed9755d81ccb059dc7f.webp",980,1287]